TOP > 外国特許検索 > MEDICINE FOR PREVENTING OR TREATING TISSUE FIBROTIC DISEASES

MEDICINE FOR PREVENTING OR TREATING TISSUE FIBROTIC DISEASES

外国特許コード F210010275
整理番号 6405
掲載日 2021年1月8日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2020JP007901
国際公開番号 WO 2020175597
国際出願日 令和2年2月27日(2020.2.27)
国際公開日 令和2年9月3日(2020.9.3)
優先権データ
  • 特願2019-035081 (2019.2.28) JP
発明の名称 (英語) MEDICINE FOR PREVENTING OR TREATING TISSUE FIBROTIC DISEASES
発明の概要(英語) Provided is a medicinal composition to be used for preventing and/or treating tissue fibrotic diseases. The medicinal composition according to the present invention, which comprises a PI3Kδ inhibitor as an active ingredient, exhibits excellent effects on tissue fibrosis in various organs and, therefore, can prevent and/or treat tissue fibrotic diseases. As an example of the PI3Kδ inhibitor, [(3S)-3-({6-[2-(difluoromethyl)-1H-benzoimidazol-1-yl]-2-(morpholin-4-yl)pyrimidin-4-yl}amino)pyrrolidin-1-yl](oxan-4-yl)methanone or a salt thereof may be cited.
従来技術、競合技術の概要(英語) Background Art
Tissue fibrosis is a bioadaptive response in the healing process of damaged tissue. Tissue fibrosis is mainly caused by abnormal growth of connective tissue in the tissue and excessive deposition of extracellular matrix such as collagen produced by fibroblasts.
Scleroderma is a systemic disease mainly composed of inflammatory and fibrotic changes, mainly composed of vascular disorders. (Non-Patent Document 1 and Non-Patent Document 2), wherein various cytokines are considered to be involved in fibrosis mainly in TGF-/ S and IL-6. In addition, although the skin fat layer is decreased in the skin of a scleroderma patient, in recent years, skin fat cell precursor cells control skin myofibroblasts and fibrosis in scleroderma (Non-Patent Document 3), Serum of a scleroderma patient inhibits differentiation of adipose-derived stem cells (Ad i pose-i nduced stem ce l l s) into adipocytes, Non-Patent Document 4) has been shown to reduce expression of perlipin (pe r i l i p i n) and adiponectin (ad i ponect i n) which are markers of adipocytes and change them like myofibroblasts, and it is believed that recovery of skin adipocytes may contribute to suppression of fibrosis. Adiponectin is one of cytokines produced by adipocytes, such as adipocyte differentiation promoting action, anti-inflammatory action, antifibrotic action (Non-Patent Document 1, Non-Patent Document 5, Non-Patent Document 7), Non-Patent Document 6), and Non-Patent Document 7), and Non-Patent Document 7), which also suggests the relationship between the scleroderma pathology and adipose tissue. Although the pathology of scleroderma has been elucidated, the therapeutic method
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • ASTELLAS PHARMA INC.
  • 発明者(英語)
  • ASHIDA, Noboru
  • NARUMIYA, Shuh
  • HIRAYAMA, Yoshitaka
  • ARAMORI, Ichiro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
上記の特許・技術に関心のある方は、下記「問合せ先」まで直接お問い合わせください。

PAGE TOP

close
close
close
close
close
close